| Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021 KL Ong, LK Stafford, SA McLaughlin, EJ Boyko, SE Vollset, AE Smith, ... The Lancet 402 (10397), 203-234, 2023 | 1801 | 2023 |
| Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies S Xu, I Ilyas, PJ Little, H Li, D Kamato, X Zheng, S Luo, Z Li, P Liu, J Han, ... Pharmacological reviews 73 (3), 924-967, 2021 | 736 | 2021 |
| The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019 KB Tran, JJ Lang, K Compton, R Xu, AR Acheson, HJ Henrikson, ... The Lancet 400 (10352), 563-591, 2022 | 630 | 2022 |
| Flavonoid biosynthetic pathways in plants: Versatile targets for metabolic engineering SM Nabavi, D Šamec, M Tomczyk, L Milella, D Russo, S Habtemariam, ... Biotechnology advances 38, 107316, 2020 | 562 | 2020 |
| Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 BS Sheena, L Hiebert, H Han, H Ippolito, M Abbasi-Kangevari, ... The lancet Gastroenterology & hepatology 7 (9), 796-829, 2022 | 517 | 2022 |
| Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the … M Naghavi, KL Ong, A Aali, HS Ababneh, YH Abate, C Abbafati, ... The Lancet 403 (10440), 2100-2132, 2024 | 430 | 2024 |
| Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease … M Brauer, GA Roth, AY Aravkin, P Zheng, KH Abate, YH Abate, C Abbafati, ... The Lancet 403 (10440), 2162-2203, 2024 | 426 | 2024 |
| Salvia miltiorrhizaBurge (Danshen): a golden herbal medicine in cardiovascular therapeutics Z Li, S Xu, P Liu Acta Pharmacologica Sinica 39 (5), 802-824, 2018 | 411 | 2018 |
| Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 JD Steinmetz, KM Seeher, N Schiess, E Nichols, B Cao, C Servili, ... The Lancet Neurology 23 (4), 344-381, 2024 | 410 | 2024 |
| Cardiovascular actions and therapeutic potential of tanshinone IIA S Gao, Z Liu, H Li, PJ Little, P Liu, S Xu Atherosclerosis 220 (1), 3-10, 2012 | 398 | 2012 |
| Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020 D Bryazka, MB Reitsma, MG Griswold, KH Abate, C Abbafati, ... The Lancet 400 (10347), 185-235, 2022 | 376 | 2022 |
| Berberine in cardiovascular and metabolic diseases: from mechanisms to therapeutics X Feng, A Sureda, S Jafari, Z Memariani, D Tewari, G Annunziata, ... Theranostics 9 (7), 1923, 2019 | 353 | 2019 |
| Transforming growth factor-β signalling: role and consequences of Smad linker region phosphorylation D Kamato, ML Burch, TJ Piva, HB Rezaei, MA Rostam, S Xu, W Zheng, ... Cellular signalling 25 (10), 2017-2024, 2013 | 329 | 2013 |
| LOX-1 in atherosclerosis: biological functions and pharmacological modifiers S Xu, S Ogura, J Chen, PJ Little, J Moss, P Liu Cellular and Molecular Life Sciences 70, 2859-2872, 2013 | 326 | 2013 |
| Curcumin, the golden spice in treating cardiovascular diseases H Li, A Sureda, HP Devkota, V Pittalà, D Barreca, AS Silva, D Tewari, ... Biotechnology advances 38, 107343, 2020 | 325 | 2020 |
| Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies S Xu, I Ilyas, J Weng Acta Pharmacologica Sinica 44 (4), 695-709, 2023 | 303 | 2023 |
| Global burden of chronic respiratory diseases and risk factors, 1990–2019: an update from the Global Burden of Disease Study 2019 S Momtazmanesh, SS Moghaddam, SH Ghamari, EM Rad, N Rezaei, ... EClinicalMedicine 59, 2023 | 288 | 2023 |
| Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics Y Duan, K Gong, S Xu, F Zhang, X Meng, J Han Signal Transduction and Targeted Therapy 7 (1), 265, 2022 | 236 | 2022 |
| Antioxidants in cardiovascular therapy: panacea or false hope? K Goszcz, SJ Deakin, GG Duthie, D Stewart, SJ Leslie, IL Megson Frontiers in cardiovascular medicine 2, 29, 2015 | 233 | 2015 |
| ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: an updated review X Feng, L Zhang, S Xu, A Shen Progress in lipid research 77, 101006, 2020 | 196 | 2020 |
Wuzhou WanNational Institutes of Health確認したメール アドレス: niaid.nih.gov
Wuzhou WanNational Institutes of Health確認したメール アドレス: niaid.nih.gov